戻る
AC Immune SA (ACIU)価格
ACIU 株価推移チャート
ACIU 収入
AC Immune SA
$3.51
-3.3%
$-0.12
終値： Jan 16, 16:00:00 GMT-5
$3.5
-0.28%
$0
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$3.63
始値
$3.6
当日レンジ
$3.47 - $3.67
52週レンジ
$1.43 - $4
取引高
186.6K
平均取引高
713.5K
1株当たり利益(TTM)
-0.72
配当利回り
--
時価総額
$351.4M
ACIUとは何ですか？
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.